Submitted:
01 April 2025
Posted:
01 April 2025
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Materials and Methods
2.1. Preparation and Implementation for CT-Scan
2.2. SCORE2-Diabetic Calculation
2.3. Statistical Analysis
3. Results
3.1. Baseline Characteristics
3.2. Coronary Artery Characteristics on Computed Tomographic Angiography
3.3. Correlation Between Coronary Artery Calcium Score and SCORE2–Diabetes
4. Discussion
4.1. Baseline Characteristics
4.2. Coronary Artery Characteristic on Computed Tomographic Angiography
4.3. Correlation Between CACS and SCORE2–Diabetes Score
5. Limitation
6. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
Abbreviations
| CVD | Cardiovascular Disease |
| T2DM | Type 2 Diabetes Mellitus |
| SCORE | Systematic Coronary Risk Evaluation |
| CACS | Coronary Artery Calcium Score |
| CCTA | Coronary Computed Tomography Angiography |
| CAD | Coronary Artery Disease |
| Hba1C | Hemoglobin A1c |
| eGFR | Estimated Glomerular Filtration Rate |
| ECG | Electrocardiogram |
| PCI | Percutaneous Coronary Intervention |
| MI | Myocardial Infarction |
| AF | Atrial Fibrillation |
| AUC | Area Under the Curve |
| ROC | Receiver Operating Characteristic |
| NCAD | Narrow Coronary Artery Disease |
| OCAD | Occlusive Coronary Artery Disease |
| LM | Left Main |
| LAD | Left Anterior Descending |
| LCx | Left Circumflex |
| RCA | Right Coronary Artery |
| SPSS | Statistical Package for the Social Sciences |
References
- World Health Organization. Cardiovascular diseases (CVDs). Lancet. 2021. Available online: https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds) (accessed on 13 March 2025).
- GBD 2021 Diabetes Collaborators. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet 2023, 402, 203–234. [Google Scholar] [CrossRef] [PubMed]
- Booth, G.L.; Kapral, M.K.; Fung, K.; Tu, J.V. Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study. Lancet 2006, 368, 29–36. [Google Scholar] [CrossRef] [PubMed]
- Piepoli, M.F.; Hoes, A.W.; Agewall, S.; Albus, C.; Brotons, C.; Catapano, A.L.; et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2016, 37, 2315–2381. [Google Scholar] [CrossRef] [PubMed]
- SCORE2 Working Group, ESC Cardiovascular Risk Collaboration. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J. 2021, 42, 2439–2454. [Google Scholar] [CrossRef] [PubMed]
- SCORE2-Diabetes Working Group, ESC Cardiovascular Risk Collaboration. SCORE2-Diabetes: 10-year cardiovascular risk estimation in type 2 diabetes in Europe. Eur Heart J. 2023, 44, 2544–2556. [Google Scholar] [CrossRef] [PubMed]
- McEvoy, J.W.; McCarthy, C.P.; Bruno, R.M.; Brouwers, S.; Canavan, M.D.; Ceconi, C.; et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024, 45, 3912–4018. [Google Scholar] [CrossRef] [PubMed]
- Grundy, S.M.; Stone, N.J.; Bailey, A.L.; Beam, C.; Birtcher, K.K.; Blumenthal, R.S.; et al. 2018 AHA/ACC guideline on the management of blood cholesterol: executive summary. J Am Coll Cardiol. 2019, 73, 3168–3209. [Google Scholar] [CrossRef] [PubMed]
- Ene-Iordache, B.; Perico, N.; Bikbov, B.; Carminati, S.; Remuzzi, A.; Perna, A.; et al. Chronic kidney disease and cardiovascular risk in six regions of the world (ISN-KDDC): a cross-sectional study. Lancet Glob Health. 2016, 4, e307–e319. [Google Scholar] [CrossRef] [PubMed]
- Arnett, D.K.; Blumenthal, R.S.; Albert, M.A.; Buroker, A.B.; Goldberger, Z.D.; Hahn, E.J.; et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: executive summary. Circulation. 2019, 140, e563–e595. [Google Scholar] [CrossRef] [PubMed]
- Visseren, F.L.J.; Mach, F.; Smulders, Y.M.; Carballo, D.; Koskinas, K.C.; Bäck, M.; et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021, 42, 3227–3337. [Google Scholar] [CrossRef] [PubMed]
- Rana, J.S.; Dunning, A.; Achenbach, S.; Al-Mallah, M.; Budoff, M.J.; Cademartiri, F.; et al. Differences in prevalence, extent, severity, and prognosis of coronary artery disease among patients with and without diabetes undergoing coronary computed tomography angiography. Diabetes Care. 2012, 35, 1787–1794. [Google Scholar] [CrossRef] [PubMed]
- Zhang, H.W.; Jin, J.L.; Cao, Y.X.; Guo, Y.L.; Wu, N.Q.; Zhu, C.G.; et al. Association of diabetes mellitus with clinical outcomes in patients with different coronary artery stenosis. Cardiovasc Diabetol. 2021, 20, 214. [Google Scholar] [CrossRef] [PubMed]
- Alluri, K.; Shaw, L.J.; Berman, D.S.; Callister, T.Q.; Raggi, P.; et al. Distribution and burden of newly detected coronary artery calcium: Results from the Multi-Ethnic Study of Atherosclerosis. J Cardiovasc Comput Tomogr. 2015, 9, 337-344.e1. [Google Scholar] [CrossRef] [PubMed]
- Raggi, P.; Shaw, L.J.; Berman, D.S.; Callister, T.Q. Prognostic value of coronary artery calcium screening in subjects with and without diabetes. J Am Coll Cardiol. 2004, 43, 1663–1669. [Google Scholar] [CrossRef] [PubMed]
- Greenland, P.; Bonow, R.O.; Brundage, B.H.; Budoff, M.J.; Eisenberg, M.J.; Grundy, S.M.; et al. ACCF/AHA 2007 clinical expert consensus document on coronary artery calcium scoring by computed tomography. J Am Coll Cardiol. 2007, 49, 378–402. [Google Scholar] [CrossRef] [PubMed]
- Anand, D.V.; Lim, E.; Darko, D.; Bassett, P.; Hopkins, D.; Lipkin, D.; et al. Determinants of progression of coronary artery calcification in type 2 diabetes. J Am Coll Cardiol. 2007, 50, 2218–2225. [Google Scholar] [CrossRef] [PubMed]
- Agarwal, S.; Morgan, T.; Herrington, D.M.; Xu, J.; Cox, A.J.; Freedman, B.I.; et al. Coronary calcium score and prediction of all-cause mortality in diabetes. Diabetes Care. 2011, 34, 1219–1224. [Google Scholar] [CrossRef] [PubMed]
- Hou, Z.H.; Lu, B.; Gao, Y.; Jiang, S.L.; Wang, Y.; Li, W.; et al. Prognostic value of coronary CT angiography and calcium score for major adverse cardiac events in outpatients. JACC Cardiovasc Imaging. 2012, 5, 990–999. [Google Scholar] [CrossRef] [PubMed]
- Kasim, S.S.; Ibrahim, N.; Malek, S.; Ibrahim, K.S.; Aziz, M.F.; Song, C.; et al. Validation of the general Framingham Risk Score. Lancet Reg Health West Pac. 2023, 35, 100742. [Google Scholar] [PubMed]
- Marx, N.; Federici, M.; Schütt, K.; Müller-Wieland, D.; Ajjan, R.A.; Antunes, M.J.; et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023, 44, 4043–4140. [Google Scholar] [CrossRef] [PubMed]

| Patients (n=100) | |
|---|---|
| Age (years) | 61.9 ± 5.4 |
| Female (n, %) | 29 (29.0) |
| Hypertension (n, %) | 88 (88.0) |
| Blood pressure (mmHg) | 150.6 ± 16.1 |
| Dyslipidemia (n, %) | 82 (82.0%) |
| Active smoking (n, %) | 57 (57.0%) |
| Age of diagnosis T2DM (years) | 58.0 ± 5.6 |
| Duration of T2DM (years) | 4.0 ± 3.3 |
| Glucose (mmol/L) | 7.7 ± 2.6 |
| HbA1c (%Hb) | 7.0 ± 1.1 |
| Ure (mmol/L) | 5.4 ± 1.5 |
| Creatinin (µmol/L) | 88.2 ± 16.4 |
| eGFR (mL/min) | 77.0 ± 13.5 |
| Total Cholesterol (mmol/L) | 4.5 ± 1.5 |
| HDL-Cholesterol (mmol/L) | 1.2 ± 0.3 |
| LDL -Cholesterol (mmol/L) | 2.5 ± 1.2 |
| Triglycerid (mmol/L) | 2.3 ± 1.4 |
| CCTA feature | Patients (n=100) | |
|---|---|---|
| CCTA | Patent | 20 (20.0%) |
| < 50% (NCAD) (n, %) | 27 (27.0%) | |
| ≥ 50% (OCAD) (n, %) | 53 (53.0%) | |
| Coronary artery stenosis | LM (n, %) | 16 (16.0%) |
| LAD (n, %) | 69 (69.0%) | |
| LCx (n, %) | 34 (34.0%) | |
| RCA (n, %) | 47 (47.0%) | |
| Number of stenotic coronary artery branches | 1 (n, %) | 27 (27.0%) |
| 2 (n, %) | 27 (27.0%) | |
| 3 (n, %) | 19 (19.0%) | |
| 4 (n, %) | 7 (7.0%) | |
| Patients (n = 100) |
Coronary Artery Calcium Score | ||
|---|---|---|---|
| LM | Stenosis | 16 | 251.6 ± 210.5 |
| Patent | 84 | 113.1 ± 284.4 | |
| LAD | Stenosis | 69 | 181.6 ± 307.8 |
| Patent | 31 | 32.1 ± 154.2 | |
| LCX | Stenosis | 34 | 257.0 ± 393.1 |
| Patent | 66 | 72.6 ± 165.1 | |
| RCA | Stenosis | 47 | 232.3 ± 359.4 |
| Patent | 53 | 49.2 ± 128.5 | |
| Feature | Patent (n=19) |
NCAD (n=31) |
OCAD (n=50) |
p–value | ||
|---|---|---|---|---|---|---|
| Age (years) | 61.2 | 62.6 | 61.7 | 0.633 | ||
| Gender | Male (n, %) | 13 (18.3%) | 19 (26.8%) | 39 (54.9%) | 0.263 | |
| Female (n, %) | 6 (20.7%) | 12 (41.4%) | 11 (37.9%) | |||
| Hypertension (n, %) | 15 (17.0%) | 28 (31.8%) | 45 (51.1%) | 0.402 | ||
| Blood pressure (mmHg) | 143.7±12.6 | 148.1±12.8 | 154.8±18.0 | 0.019 | ||
| Smoking (n, %) | 6 (11.3%) | 13 (24.5%) | 34 (64.2%) | 0.008 | ||
| Dyslipidemia (n, %) | 17 (20.7%) | 25 (30.5%) | 40 (48.8%) | 0.640 | ||
| Age of diagnosis T2DM (years) | 57.1 ± 4.3 | 58.7 ± 5.5 | 57.8 ± 6.2 | 0.585 | ||
| Glucose (mmol/L) | 7.8 ± 2.5 | 7.7 ± 2.8 | 7.6 ± 2.5 | 0.95 | ||
| HbA1c (%Hb) | 6.8 ± 0.9 | 7.1 ± 1.1 | 7.2 ± 1.1 | 0.38 | ||
| Ure (mmol/L) | 5 ± 0.9 | 5.6 ± 1.8 | 5.5 ± 1.5 | 0.312 | ||
| Creatinin (µmol/L) | 91.5 ± 14.5 | 89.2 ± 20.3 | 86.3 ± 14.4 | 0.46 | ||
| eGFR (mL/min) | 71.9 ± 14.4 | 74.9 ± 12.4 | 80.3 ± 13.1 | 0.036 | ||
| Total Cholesterol (mmol/L) | 4 ± 0.6 | 4.8 ± 1.3 | 4.5 ± 1.7 | 0.240 | ||
| HDL - Cholesterol (mmol/L) | 1.1 ± 0.3 | 1.3 ± 0.3 | 1.1 ± 0.2 | 0.027 | ||
| LDL – Cholesterol (mmol/L) | 1.9 ± 0.6 | 2.8 ± 1.1 | 2.5 ± 1.4 | 0.048 | ||
| SCORE2–Diabetes Low risk | 10.1 ± 2.9 | 11.6 ± 3.5 | 12.8 ± 4.1 | 0.027 | ||
| SCORE2–Diabetes Moderate risk | 13.3 ± 4 | 15.3 ± 4.9 | 17.1 ± 5.8 | 0.027 | ||
| SCORE2–Diabetes High risk | 17 ± 4.7 | 20.6 ± 7.2 | 21.9 ± 7.1 | 0.032 | ||
| SCORE2–Diabetes Very high risk | 26.9 ± 5.7 | 31.4 ± 8.9 | 32.6 ± 8.5 | 0.038 | ||
| CACS | 2.2 ± 5.1 | 14.6 ± 18.3 | 260.6 ± 351.4 | < 0.001 | ||
| CAC classification | 0 | 13 (40.6%) | 14 (43.8%) | 5 (15.6%) | < 0.001 | |
| 1–100 | 6 (14.6%) | 17 (41.5%) | 18 (43.9%) | |||
| 101– 400 | 0 (0.0%) | 0 (0.0%) | 17 (100.0%) | |||
| > 400 | 0 (0.0%) | 0 (0.0%) | 10 (100.0%) | |||
| Spearman’s rho | Coronary Artery Calcium Score | p–value |
|---|---|---|
| SCORE2–Diabetes Low risk | 0,28 | 0,005 |
| SCORE2–Diabetes Moderate risk | 0,28 | 0,005 |
| SCORE2–Diabetes High risk | 0,28 | 0,005 |
| SCORE2–Diabetes Very high risk | 0,27 | 0,005 |
| Feature | Patent (n=20) |
Single vessel disease (n=27) |
>1 vessel disease (n=53) |
p value | |
|---|---|---|---|---|---|
| CACS | 2.1±4.9 | 67.6±182.7 | 220.0±337.1 | 0.003 | |
| CACS classification | 0 | 14 (43.8%) | 9 (28.1%) | 9 (28.1%) | < 0.001 |
| 1–100 | 6 (14.6%) | 15 (36.5%) | 20 (58.8%) | ||
| 101– 400 | 0 (0.0%) | 1 (5.9%) | 16 (94.1%) | ||
| > 400 | 0 (0.0%) | 2 (20.0%) | 8 (80.0%) | ||
| Coronary artery stenosis | Patent | 19 (100.0%) | 0 (0.0%) | 0 (0.0%) | < 0.001 |
| < 50% | 1 (3.2%) | 17 (54.8%) | 13 (41.9%) | ||
| ≥ 50 % | 0 (0.0%) | 10 (20.0%) | 40 (80.0%) | ||
| SCORE2-Diabetes | |||||
| SCORE2-Diabetes Low risk | 10.3±2.9 | 10.9±2.8 | 13.0±4.3 | 0.006 | |
| SCORE2-Diabetes Moderate risk | 13.5±4.1 | 14.4±4.0 | 17.4±6.0 | 0.006 | |
| SCORE2-Diabetes High risk | 17.3±4.7 | 19.5±5.0 | 22.3±8.0 | 0.012 | |
| SCORE2-Diabetes Very high risk | 27.2±6.0 | 30.6±6.4 | 33.0±9.5 | 0.025 | |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).